Trinity Biotech plc (NASDAQ:TRIB) Short Interest Up 58.3% in April

Trinity Biotech plc (NASDAQ:TRIB) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,900 shares, an increase of 58.3% from the March 31st total of 1,200 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 94,300 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Trinity Biotech in a report on Wednesday. They issued a “buy” rating for the company.

Trinity Biotech Price Performance

Trinity Biotech stock remained flat at $1.83 during midday trading on Friday. The company’s stock had a trading volume of 4,535 shares, compared to its average volume of 15,919. Trinity Biotech has a 12 month low of $1.79 and a 12 month high of $5.50. The company’s fifty day simple moving average is $2.01 and its 200 day simple moving average is $2.24. The company has a market capitalization of $13.94 million, a price-to-earnings ratio of -0.58 and a beta of 1.21.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) earnings per share for the quarter. The firm had revenue of $13.43 million during the quarter. As a group, equities analysts predict that Trinity Biotech will post -1.5 EPS for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.